









Markets
/
Stocks
/
nasdaq-acad
/

ACADIA Pharmaceuticals Inc

ACAD

22.200USD

-0.370-1.64%

Close 11/10, 16:00（ET）Quotes delayed by 15 min

3.76BMarket Cap

14.38P/E TTM



ACADIA Pharmaceuticals Inc

22.200

-0.370-1.64%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ACADIA Pharmaceuticals Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ACADIA Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

12 / 407

Overall Ranking

63 / 4611

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 21 analysts

Buy

Current Rating

28.667

Target Price

+27.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ACADIA Pharmaceuticals Inc Highlights

StrengthsRisks

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 85.18% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Fairly Valued

The company’s latest PE is 14.17, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 173.25M shares, decreasing 8.22% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 3.17M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-10

The company's current financial score is 9.33, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 278.63M, representing a year-over-year increase of 11.27%, while its net profit experienced a year-over-year increase of 119.07%.

Score

Industry at a Glance

Previous score

9.33

Change



Financials

8.86

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.81

Key Metrics

Free cash flow

No Data

ACADIA Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-10

The company’s current valuation score is 6.50, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 14.17, which is 629.18% below the recent high of 103.35 and 15353.08% above the recent low of -2161.97.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-10

The company’s current earnings forecast score is 7.52, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for ACADIA Pharmaceuticals Inc is 29.00, with a high of 39.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

7.52

Change

Support & Resistance

No Data

Analyst Rating

Based on 21 analysts

Buy

Current Rating

28.667

Target Price

+27.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

ACADIA Pharmaceuticals Inc

ACAD

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-10

The company’s current price momentum score is 8.72, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 23.95 and the support level at 20.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.87

Change

-0.15

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(5)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.168

Neutral

RSI(14)

50.783

Neutral

STOCH(KDJ)(9,3,3)

54.280

Neutral

ATR(14)

0.929

High Vlolatility

CCI(14)

35.148

Neutral

Williams %R

46.939

Neutral

TRIX(12,20)

0.116

Sell

StochRSI(14)

59.216

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

22.120

Buy

MA10

22.356

Sell

MA20

21.876

Buy

MA50

22.549

Sell

MA100

22.967

Sell

MA200

20.577

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-10

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 102.40%, representing a quarter-over-quarter decrease of 1.94%. The largest institutional shareholder is The Vanguard, holding a total of 15.15M shares, representing 8.96% of shares outstanding, with 7.03% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

42.90M

+0.04%

BlackRock Institutional Trust Company, N.A.

18.22M

-2.94%

The Vanguard Group, Inc.

Star Investors

15.24M

+0.40%

RTW Investments L.P.

9.00M

+5.33%

State Street Investment Management (US)

6.18M

-11.66%

Morgan Stanley & Co. LLC

3.19M

-25.06%

Point72 Asset Management, L.P.

Star Investors

3.17M

-31.74%

Geode Capital Management, L.L.C.

3.02M

+2.36%

Citadel Advisors LLC

3.01M

+922.43%

Palo Alto Investors LP

2.56M

-3.78%

Risk Assessment

Currency: USD Updated: 2025-11-10

The company’s current risk assessment score is 6.51, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.68. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.